Beta-cell recovery to counter diabetes

Introduction

Globally, 8.75 million people with T1D rely only on insulin administration to manage the symptoms of their disease. The treatment is complex since it requires injecting insulin 2-4 times a day and adhering to a restrictive lifestyle (e.g., following a strict diet), reducing patient quality of life (QoL).

Challenges in Treatment

Even with insulin, less than 20% of patients achieve their target glucose level. This inadequacy eventually leads to vascular complications, such as:

• Stroke
• Renal disease

These complications can reduce life expectancy by 10-15 years.

DiogenX's Mission

DiogenX aims to withdraw insulin dependency and cure T1D by regenerating pancreatic beta cells. This regeneration would allow for autonomous insulin release in response to increases in blood glucose levels.

Future Plans

We expect to out-license our drug to a pharma company. Some companies have already shown interest and invested in the capital of DiogenX. This may materialize as soon as clinical proof of principle is demonstrated in humans, which we anticipate will be reached in 2026.

Funding and Timeline

The proceeds from Series A, which is to be raised in 2023, are 80% secured.